贝伐珠单抗联合紫杉醇治疗转移性乳腺癌临床疗效及预后分析

Efficacy of bevacizumab combined with paclitaxel in the treatment of metastatic breast cancer and the prognosis

目的探讨贝伐珠单抗联合紫杉醇治疗转移性乳腺癌的疗效及预后情况。方法选取2020年6月至2021年6月间复旦大学附属华山医院收治的120例转移性乳腺癌患者作为研究对象,根据治疗方法不同进行分组,对照组57例患者单纯采用紫杉醇治疗,观察组63例患者在对照组基础上加用贝伐珠单抗治疗,28 d为1个疗程,两组均接受4个疗程化疗治疗。对比两组患者临床疗效、不良反应发生情况,随访6个月后两组患者无进展生存时间(PFS)及总生存时间(OS)情况。结果观察组患者临床治疗总有效率69.8%(44/63),高于对照组患者的49.1%(28/57),差异有统计学意义(P<0.05)。观察组头痛(11.1%)、高血压(12.7%)和蛋白尿(14.3%)总发生率均高于对照组的1.8%、1.8%和3.5%,差异均有统计学意义(均P<0.05)。观察组PFS、OS水平高于对照组,差异有统计学意义(P<0.05)。结论贝伐珠单抗联合紫杉醇治疗转移性乳腺癌效果较好,能够明显抑制患者疾病进展,延长生存时间,但存在不同程度的不良反应,需引起临床重视。

Objective To investigate the efficacy of bevacizumab combined with paclitaxel in the treatment of metastatic breast cancer and prognosis in this population.Methods A total of 120 patients with metastatic breast cancer who were admitted to Huashan Hospital Affiliated to Fudan University were selected from June 2020 to June 2021.The patients were randomly divided into an observation group(63 patients)in which patients received bevacizumab in addition to paclitaxel and a control group(57 patients)in which patients only received paclitaxel based the therapies they received.A course of treatment last for 28 dayss.Both groups received 4 courses of chemotherapy.Clinical efficacy and adverse reactions were compared between the two groups.After 6 months of follow-up,the progression-free survival(PFS)and overall survival(OS)were compared between the two groups.Result The overall efficacy rate of clinical treatment was 69.8%(44/63)in observation group,which was significantly higher than 49.1%(28/57)of the control group(P<0.05).The incidence of headache(11.1%),hypertension(12.7%)and proteinuria(14.3%)were significantly higher in the observation group than 1.8%,1.8%,3.5%,respectively of the control group(all P<0.05).Progression free survival and overall survival was significantly higher in the observation group than in the control group(all P<0.05).Conclusion Bevacizumab combined with paclitaxel shows a good effect in the treatment of metastatic breast cancer,which can significantly inhibit the disease progression and prolong the survival.